Danske Bank’s Alnylam Pharmaceuticals ALNY Stock Holding History

Danske Bank’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$19.4M	Sell	64,555 -1,400	-2%	-$422K	0.04%	325
2026 Q1	$21.8M	Sell	65,955 -1,246	-2%	-$424K	0.05%	278
2025 Q4	$26.7M	Buy	67,201 +9,794	+17%	+$4.33M	0.06%	253
2025 Q3	$26.2M	Buy	57,407 +2,400	+4%	+$977K	0.07%	244
2025 Q2	$17.9M	Buy	55,007 +1,802	+3%	+$499K	0.04%	314
2025 Q1	$14.4M	Sell	53,205 -8,808	-14%	-$2.26M	0.04%	327
2024 Q4	$14.6M	Buy	62,013 +9,608	+18%	+$2.53M	0.04%	339
2024 Q3	$14.4M	Buy	52,405 +100	+0.2%	+$26K	0.05%	324
2024 Q2	$12.7M	Sell	52,305 -17,186	-25%	-$2.71M	0.05%	324
2024 Q1	$10.4M	Buy	+69,491	New	+$11.6M	0.03%	412

Other funds holding ALNY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Danske Bank's ALNY Position: Q2 2026 in Review

Danske Bank reduced its Alnylam Pharmaceuticals (ALNY) stake by 2.1% in Q2 2026, selling an estimated $422K and leaving 64,555 shares worth $19.4M. The position accounts for 0.04% of the portfolio, ranked #325.

Danske Bank first reported a position in ALNY in Q1 2024 and has held it in 10 quarters since. The position peaked at $26.7M in Q4 2025. 677 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Danske Bank held 64,555 shares of Alnylam Pharmaceuticals worth $19.4M as of Q2 2026.
Danske Bank sold 1,400 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $422K.
Alnylam Pharmaceuticals made up 0.04% of Danske Bank's portfolio in Q2 2026, its #325 holding.
Danske Bank first reported a position in Alnylam Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
Danske Bank's Alnylam Pharmaceuticals position peaked at $26.7M in Q4 2025.
677 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Danske Bank's 13F filing for Q2 2026, filed 10 Aug 2026.